Gamalate B6

Pharmacological properties

bamalate b6 contains a combination of active substances: gamma, amino-β-hydroxybutyric acid, vitamin b6 (pyridoxine hydrochloride), which are natural components of the brain tissue, and magnesium glutamate hydrobromide (mg). the drug has a neuroregulatory effect on processes in the brain, and causes mild sedative and cerebro-tonic effects.

GABA is formed in the brain due to the decarboxylation of glutamic acid. This reaction is catalyzed by the enzyme glutamine decarboxylase (HDA) and coenzyme - vitamin B₆. The reaction produces amino-β-hydroxybutyric acid (GABOM). GABOM has an anticonvulsant effect, which is realized through the cholinergic mechanism, improves memory and learning ability.

In addition, GABA can again turn into its precursor (glutamic acid) through the transamination mechanism, which is catalyzed by the enzyme GABA-α-ketoglutarate transaminase (GABA-T), vitamin B also acts as a coenzyme₆. Through this transamination mechanism, GABA is involved in the oxygenation of the brain.

GABA is converted to glutamic acid, which is converted to aspartic acid, which forms the substrate for the Krebs cycle in the brain.

Thus, the level of GABA in the central nervous system depends on the balance of the enzymes GDK and GABA-T.

In the event of a malfunction of the brain, inhibition occurs, which is associated with a decrease in the level of GABA - the main inhibitory neurotransmitter. Reception Gamalate B₆ provides the exogenous entry of GABA into the nervous system, and a high level of GABA, in turn, provides the following effects:

• performs neurotransmitter function and inhibits the processes of excitation;
• takes part in the transport and utilization of glucose in the brain;
• takes part in cellular respiration and oxidative phosphorylation;
• promotes the combination of certain amino acids (leucine, alanine, phenylalanine) into proteins;
• takes part in the regulation of protein synthesis in the brain.

MGH in its structure contains glutamic acid and a compound of magnesium with bromine in the form of a chelate. Thanks to the latter, MHG acts as a partial (partial) agonist of L-glutamate and causes a decrease in stimulation and a mild sedative effect. This distinguishes it from tranquilizers (benzodiazepines, barbiturates) with a direct inhibitory effect, which is associated with a high level of side effects that are not characteristic of MGH. Studies have shown the anticonvulsant activity of IGH, a positive effect in sleep disorders, neurovegetative changes and behavioral disorders in children. The calming effect of IGH is not associated with decreased attention and concentration.

Pharmacokinetics Gamalate B₆ contains 4 components, 3 of which are physiological products (GABA, GABOB and vitamin B₆) Classical pharmacokinetic studies in this case cannot be carried out because of the complexity of the quantitative determination of exogenous and endogenous components. Such a number of components of the drug also makes it impossible to conduct analysis using a radioactively labeled product due to the large radiological load.

Indications

It is prescribed to adults as an aid in functional asthenia with manifestations:

• emotional lability;
• impaired concentration of attention and memory;
• depression and asthenia;
• low adaptability.

Application

Applied in adults by mouth, 2 tablets 2-3 times a day.

The duration of treatment depends on the condition of the patient and the course of the disease and is 2-18 months.

Contraindications

Hypersensitivity to the components of the drug.

Side effects

When used in high doses, dyspeptic disorders are possible, which disappear with dose adjustment.the appearance of allergic reactions is not excluded.

special instructions

Use during pregnancy and lactation. during pregnancy and lactation, the drug is used only under the supervision of a doctor and taking into account the benefit / risk ratio.

Children. In pediatric practice, a solution is used in the form of a solution for oral administration.

The ability to influence the reaction rate when driving vehicles and working with other mechanisms. Not described.

Interactions

Not described.

Overdose

The drug has low toxicity, so the likelihood of intoxication is not provided.

Storage conditions

At a temperature below 30 ° C.